Insulin-Liposomes

Liposomes are utilised as a delivery carrier in insulin therapy for several reasons; an enhancement in the oral absorption of insulin, the ability to selectively target insulin to the hepatic system, and prolong drug action for proper dose regimen. The hepatocytic delivery of insulin can be achieved efficiently through the insulin liposomal method. While treating diabetes with liver-targeted liposomes, it is expected that constraints will arise due to the formulation being supplied by an intravenous route. Furthermore, due to the dilute concentration of insulin in the liposomal formulation, the overall cost of the liposomal insulin would rise. The consequence of encapsulating the drug in the liposomal carrier is improved oral absorption of insulin. Drug action can be continued by giving subcutaneous liposomal insulin. Insulin remains at the site of injection, and the occurrence of a lipid matrix for subcutaneous insulin delivery raises concerns about over-improved antigenicity. The liposomal insulin sustains the role of a delivery system in understanding and treating diabetes using the hepatically targeted liposomal system. This pharmacological aspect has highlighted the role of the liver in the metabolic complications associated with diabetes mellitus.